BioXcel Therapeutics, Inc. (BTAI)
BTAI Stock Price Chart
Explore BioXcel Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze BTAI price movements and trends.
BTAI Company Profile
Discover essential business fundamentals and corporate details for BioXcel Therapeutics, Inc. (BTAI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Mar 2018
Employees
37.00
CEO
Vimal D. Mehta
Description
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
BTAI Financial Timeline
Browse a chronological timeline of BioXcel Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.42, while revenue estimate is $403.32k.
Earnings released on 15 May 2026
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $206.00k , missing expectations by -46.00%.
Earnings released on 26 Mar 2026
EPS came in at -$0.58 falling short of the estimated -$0.34 by -70.59%, while revenue for the quarter reached $256.00k , beating expectations by +68.95%.
Earnings released on 12 Nov 2025
EPS came in at -$2.18 falling short of the estimated -$1.54 by -41.56%, while revenue for the quarter reached $98.00k , missing expectations by -42.02%.
Earnings released on 12 Aug 2025
EPS came in at -$2.45 falling short of the estimated -$2.30 by -6.52%, while revenue for the quarter reached $120.00k , missing expectations by -53.40%.
Earnings released on 12 May 2025
EPS came in at -$1.50 surpassing the estimated -$2.72 by +44.85%, while revenue for the quarter reached $168.00k , missing expectations by -52.00%.
Earnings released on 27 Mar 2025
EPS came in at -$3.57 surpassing the estimated -$4.36 by +18.12%, while revenue for the quarter reached $366.00k , missing expectations by -49.04%.
Stock split effective on 10 Feb 2025
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$5.12 surpassing the estimated -$8.00 by +36.00%, while revenue for the quarter reached $214.00k , missing expectations by -82.77%.
Earnings released on 6 Aug 2024
EPS came in at -$3.36 surpassing the estimated -$12.16 by +72.37%, while revenue for the quarter reached $1.10m , beating expectations by +18.71%.
Earnings released on 9 May 2024
EPS came in at -$13.92 falling short of the estimated -$10.88 by -27.94%, while revenue for the quarter reached $582.00k , beating expectations by +29.33%.
Earnings released on 12 Mar 2024
EPS came in at -$12.16 surpassing the estimated -$15.68 by +22.45%, while revenue for the quarter reached $376.00k , missing expectations by -47.04%.
Earnings released on 14 Nov 2023
EPS came in at -$27.52 falling short of the estimated -$20.64 by -33.33%, while revenue for the quarter reached $341.00k , missing expectations by -53.29%.
Earnings released on 14 Aug 2023
EPS came in at -$29.28 falling short of the estimated -$27.52 by -6.40%, while revenue for the quarter reached $457.00k , beating expectations by +1.56%.
Earnings released on 8 May 2023
EPS came in at -$29.44 falling short of the estimated -$24.96 by -17.95%, while revenue for the quarter reached $206.00k , missing expectations by -58.80%.
Earnings released on 9 Mar 2023
EPS came in at -$31.20 falling short of the estimated -$23.84 by -30.87%, while revenue for the quarter reached $238.00k , missing expectations by -80.96%.
Earnings released on 10 Nov 2022
EPS came in at -$23.84 falling short of the estimated -$21.44 by -11.19%, while revenue for the quarter reached $137.00k , missing expectations by -86.37%.
Earnings released on 9 Aug 2022
EPS came in at -$21.60 falling short of the estimated -$19.20 by -12.50%.
Earnings released on 9 May 2022
EPS came in at -$17.92 surpassing the estimated -$19.36 by +7.44%.
Earnings released on 10 Mar 2022
EPS came in at -$14.88 surpassing the estimated -$18.88 by +21.19%.
Earnings released on 10 Nov 2021
EPS came in at -$15.36 surpassing the estimated -$17.28 by +11.11%.
Earnings released on 10 Aug 2021
EPS came in at -$17.76 falling short of the estimated -$16.48 by -7.77%.
BTAI Stock Performance
Access detailed BTAI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
